|
|
|
| . .. | Heavy negative responses at the German
stock exchange (-7%) when rendering the Bayer's first six-monthly data.
The market did not surely appreciate the operative benefits decrease (-3%), notwithstanding the 2% sales growth. It is clear that operators find hard to believe the German pharmaceutical house evaluations. Analysts, furthermore, seem not to deem “relatively limited “ - as the Company asserts - the impact of the Asiatic crisis over the company itself. |
 |
 |